SLC25A18 and inborn mitochondrial metabolism disorder: The identification of mitochondrial disease-specific markers (EFHD1, SASH1, FAM110B, and SLC25A18) highlights shared mechanisms, such as oxidative phosphorylation, calcium signaling, and immune responses, that can serve as therapeutic targets in both AD and GBM.